130 related articles for article (PubMed ID: 25836939)
1. Second-line therapies in metastatic urothelial carcinoma.
Narayanan S; Harshman LC; Srinivas S
Hematol Oncol Clin North Am; 2015 Apr; 29(2):341-59, x. PubMed ID: 25836939
[TBL] [Abstract][Full Text] [Related]
2. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
Sonpavde G; Pond GR; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Dreicer R; Chen YH; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Bellmunt J
Clin Genitourin Cancer; 2015 Apr; 13(2):185-92. PubMed ID: 25458370
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of upper tract urothelial carcinoma.
Lucca I; Leow JJ; Shariat SF; Chang SL
Hematol Oncol Clin North Am; 2015 Apr; 29(2):271-88, ix. PubMed ID: 25836934
[TBL] [Abstract][Full Text] [Related]
4. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure.
Siefker-Radtke AO
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1701-3. PubMed ID: 19954279
[No Abstract] [Full Text] [Related]
5. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
Pond GR; Bellmunt J; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Sonpavde G
Clin Genitourin Cancer; 2015 Feb; 13(1):71-9. PubMed ID: 24993933
[TBL] [Abstract][Full Text] [Related]
6. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
Grivas P; Yu EY
Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
[TBL] [Abstract][Full Text] [Related]
7. [Therapy for systemic urothelial cancer recurrence].
Lehmann J; Stöckle M
Urologe A; 2005 Apr; 44(4):369-74. PubMed ID: 15754166
[TBL] [Abstract][Full Text] [Related]
8. Evolving Treatment of Advanced Urothelial Cancer.
Sridhar SS
J Oncol Pract; 2017 May; 13(5):309-315. PubMed ID: 28489981
[TBL] [Abstract][Full Text] [Related]
9. INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract.
Lee HY; Li CC; Huang CN; Li WM; Yeh HC; Ke HL; Yang KF; Liang PI; Li CF; Wu WJ
J Surg Oncol; 2015 Mar; 111(4):414-22. PubMed ID: 25488476
[TBL] [Abstract][Full Text] [Related]
10. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
[TBL] [Abstract][Full Text] [Related]
11. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
[TBL] [Abstract][Full Text] [Related]
12. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
Haines L; Bamias A; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Galsky MD
Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
[TBL] [Abstract][Full Text] [Related]
13. Conditional Survival in de novo Metastatic Urothelial Carcinoma.
Pal SK; Lin YI; Yuh B; DeWalt K; Kazarian A; Vogelzang N; Nelson RA
PLoS One; 2015; 10(8):e0136622. PubMed ID: 26308952
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.
Lughezzani G; Burger M; Margulis V; Matin SF; Novara G; Roupret M; Shariat SF; Wood CG; Zigeuner R
Eur Urol; 2012 Jul; 62(1):100-14. PubMed ID: 22381168
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.
Dietrich B; Siefker-Radtke AO; Srinivas S; Yu EY
Am Soc Clin Oncol Educ Book; 2018 May; 38():342-353. PubMed ID: 30231356
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy indications in the treatment of metastases from urological malignancies].
Théodore C
Prog Urol; 2008 Nov; 18 Suppl 7():S219-22. PubMed ID: 19070795
[TBL] [Abstract][Full Text] [Related]
17. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.
Grivas PD; Melas M; Papavassiliou AG
Semin Cancer Biol; 2015 Dec; 35():125-32. PubMed ID: 26304731
[TBL] [Abstract][Full Text] [Related]
18. Options in metastatic urothelial cancer after first-line therapy.
Alimohamed NS; Sridhar SS
Curr Opin Support Palliat Care; 2015 Sep; 9(3):255-60. PubMed ID: 26262830
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in the treatment of urothelial cancers.
Aragon-Ching JB; Trump DL
Urol Oncol; 2017 Jul; 35(7):465-472. PubMed ID: 28366271
[TBL] [Abstract][Full Text] [Related]
20. Upper tract urothelial carcinoma: special considerations.
Hutchinson R; Haddad A; Sagalowsky A; Margulis V
Clin Adv Hematol Oncol; 2016 Feb; 14(2):101-9. PubMed ID: 27057809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
